Event Type
Disclosure
Mandatory
Variant
8-K
Entry into a Material Definitive Agreement. On January 21, 2026, Stoke Therapeutics, Inc. (the “Company”) entered into a new lease for its corporate headquarter
by reference. SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its beh